Respiratory Syncytial Virus (RSV) Pipeline Assessment, 2023 | In-depth Insights Into the Clinical and Non-Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Breakthroughs, Emerging Therapies, and Treatment Algorithm | Key Companies - GlaxoSmithKline (G

As per DelveInsight's assessment, globally, about 50+ pharma and biotech giants are working on 50+ pipeline drugs in the Respiratory Syncytial Virus (RSV) therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Respiratory syncytial virus (RSV) is a common cause of respiratory tract infection, particularly in children. Nearly all children have been infected by age four years, many in the first year of life. Infection does not provide complete immunity, so reinfection is common, although usually less serious. It is responsible for more than 50,000 hospitalizations every year in the United States in children under the age of 5 years.

To improve the treatment scenario, globally, several major pharma and biotech giants such as GlaxoSmithKline, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV, Shionogi, Aridis Pharmaceuticals, ADMA Biologics, Enanta Pharmaceuticals, Merck Sharp & Dohme, Janssen Research & Development, Ark Biosciences, BlueWillow Biologics, Meissa Vaccines, and others are actively working in the Respiratory syncytial virus therapeutics market.

"Respiratory Syncytial Virus Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Respiratory Syncytial Virus Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Respiratory Syncytial Virus (RSV) Pipeline Analysis
The report provides insights into:
- The report provides detailed insights into the key companies that are developing therapies in the Respiratory Syncytial Virus Market.
- The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Respiratory Syncytial Virus treatment.
- It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Respiratory Syncytial Virus market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Learn More About the Emerging Therapies and Evolving Treatment Algorithms:
https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates

Respiratory Syncytial Virus (RSV) Pipeline Drugs - Route of Administration
Products have been categorized under various ROAs, such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical

Molecule Type
Products have been categorized under various Molecule types, such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy

Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Respiratory Syncytial Virus (RSV) Therapeutics Analysis
There are approx. 50+ key companies developing therapies for Respiratory Syncytial Virus (RSV). Currently, GlaxoSmithKline is leading the therapeutics market with its Respiratory Syncytial Virus (RSV) drug candidates in the most advanced stage of clinical development among all the key players.

The Leading Companies in the Respiratory Syncytial Virus (RSV) Therapeutics Market Include:
GlaxoSmithKline, MedImmune, ReViral, Pfizer, Sanofi, BioComo, IMV, Shionogi, Aridis Pharmaceuticals, ADMA Biologics, Enanta Pharmaceuticals, Merck Sharp & Dohme, Janssen Research & Development, Ark Biosciences, BlueWillow Biologics, Meissa Vaccines, Alios BioPharma, Codagenix, Advance Vaccine Laboratories, Bavarian Nordic, ModernaTX, Inc., Virometix, Airway Therapeutics LLC, AlloVir Inc, Anima Biotech Inc, Aridis Pharmaceuticals Inc, Atea Pharmaceuticals Inc, Atriva Therapeutics, Calder Biosciences Inc, Cidara Therapeutics Inc, Clover Biopharmaceuticals, Curevac AG, Enyo Pharma SA, HanaVax Inc., Icosavax Inc, IDBiologics Inc, Pneumagen Ltd, Riboscience LLC, Signia Therapeutics, and others.

Respiratory Syncytial Virus (RSV) Therapies Covered in the Report Include:
- GSK3844766A: GlaxoSmithKline
- Nirsevimab (MEDI-8897): MedImmune
- Sisunatovir: ReViral
And Many More

Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Respiratory Syncytial Virus Current Treatment Patterns
4. Respiratory Syncytial Virus - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Respiratory Syncytial Virus Late-Stage Products (Phase-III)
7. Respiratory Syncytial Virus Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Respiratory Syncytial Virus Discontinued Products
13. Respiratory Syncytial Virus Product Profiles
14. Respiratory Syncytial Virus Key Companies
15. Respiratory Syncytial Virus Key Products
16. Dormant and Discontinued Products
17. Respiratory Syncytial Virus Unmet Needs
18. Respiratory Syncytial Virus Future Perspectives
19. Respiratory Syncytial Virus Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:

Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
Address: 428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.